邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

提高对儿童系统性红斑狼疮的认识

邓江红,  李彩凤

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(3): 276-282
邓江红, 李彩凤. 提高对儿童系统性红斑狼疮的认识[J]. 协和医学杂志, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
引用本文: 邓江红, 李彩凤. 提高对儿童系统性红斑狼疮的认识[J]. 协和医学杂志, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
shu
Jiang-hong DENG, Cai-feng LI. Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
Citation: Jiang-hong DENG, Cai-feng LI. Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(3): 276-282. doi: 10.3969/j.issn.1674-9081.20200069
shu

提高对儿童系统性红斑狼疮的认识

doi: 10.3969/j.issn.1674-9081.20200069

  • 国家儿童医学中心(北京) 首都医科大学附属北京儿童医院风湿免疫科, 北京 100045

详细信息
    通讯作者:

    李彩凤  电话:010-59616306/59616316,E-mail:caifeng_li@yeah.net

  • 中图分类号: R593.24

Improving the Acknowledge of Childhood-onset Systemic Lupus Erythematosus

  • Department of Rheumatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China

More Information
    Corresponding author: LI Cai-feng   Tel: 86-10-59616306/59616316,E-mail:caifeng_li@yeah.net

    摘要
  • 摘要: 儿童系统性红斑狼疮(childhood-onset systemic lupus erythematosus,cSLE)特指在18岁之前发病的SLE,在我国小儿全身性结缔组织病中居第二位。与成人SLE相比,cSLE在流行病学、临床表现及治疗方面都有其自身特点。近年来,随着人类基因组学和分子生物学的迅猛发展,对该病的认识也在不断加深,本文对cSLE的病因、表现及治疗最新进展进行梳理和总结,以期更好地认识该病,进而指导临床实践。
    Abstract: Childhood-onset systemic lupus erythematosus (cSLE), which refers to SLE before the age of 18, is the second systemic connective tissue disease in children. Compared with adults, cSLE has its own characteristics in epidemiology, clinical presentation, and treatment. In recent years, with the rapid development of human genomics and molecular biology, the understanding of the disease has been updated. This paper reviewed recent progress in the etiology, manifestation, and treatment of cSLE, so as to better understand this disease and guide clinical practice.
    利益冲突  无
    • HTML全文
    • 参考文献(52)
  • [1] Silva CA, Avcin T, Brunner HI. Taxonomy for systemic lupus erythematosus with onset before adulthood[J]. Arthritis Care Res (Hoboken), 2012:64:1787-1793. doi:  10.1002/acr.21757
    [2] Livingston B,Bonner A,Pope J.Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus:a meta-analysis[J].Lupus,2011,20:1345-1355. doi:  10.1177/0961203311416694
    [3] Tektonidou MG, Lewandowski LB, Hu J, et al. Survival in adults and children with systemic lupus erythematosus:a systematic review and Bayesian meta-analysis of studies from 1950 to 2016[J]. Ann Rheum Dis, 2017,76:2009-2016. doi:  10.1136/annrheumdis-2017-211663
    [4] Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6:538-546. doi:  10.1038/nrrheum.2010.121
    [5] Pineles D, Valente A, Warren B, et al. Worldwide incid-ence and prevalence of pediatric onset systemic lupus erythematosus[J]. Lupus, 2011,20:1187-1192. doi:  10.1177/0961203311412096
    [6] Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus[J]. Best Prac Res Clin Rheum,2018, 32:188-205. doi:  10.1016/j.berh.2018.09.004
    [7] Cattalini M, Soliani M, Caparello MC, et al. Sex differences in pediatric rheumatology[J]. Clin Rev Allergy Immunol, 2019,56:293-307. doi:  10.1007/s12016-017-8642-3
    [8] Mina R, Brunner HI. Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?[J]. Rheum Dis Clin North Am,2010,36:53-80. doi:  10.1016/j.rdc.2009.12.012
    [9] Watson L, Leone V, Pilkington C, et al.Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort[J].Arthritis Rheum, 2012, 64:2356-2365. doi:  10.1002/art.34410
    [10] Rees F, Doherty M, Grainge MJ, et al. Mortality in systemic lupus erythematosus in the United Kingdom 1999-2012[J]. Rheumatology (Oxford), 2016, 55:854-860. doi:  10.1093/rheumatology/kev424
    [11] Harry O, Yasin S, Brunner HI. Childhood-Onset Systemic Lupus Erythematosus:A Review and Update[J]. J Pediatr,2018,196:22-30. doi:  10.1016/j.jpeds.2018.01.045
    [12] Rahman A, Isenberg DA. Systemic lupus erythematosus[J]. N Engl J Med, 2008, 358:929-939. doi:  10.1056/NEJMra071297
    [13] Kwon Y, Chun S, Kim K, et al. Update on the Genetics of Systemic Lupus Erythematosus:Genome-Wide Association Studies and Beyond[J]. Cells,2019,8:1180. doi:  10.3390/cells8101180
    [14] Webber D, Cao J, Dominguez D, et al. Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE[J]. Rheumatology (Oxford), 2020,59:90-98. doi:  10.1093/rheumatology/kez220
    [15] Omarjee O, Picard C, Frachette C, et al. Monogenic Lupus:dissecting heterogeneity[J]. Autoimmun Rev,2019,18:102361. doi:  10.1016/j.autrev.2019.102361
    [16] Wu YL, Brookshire BP, Verani RR, et al. Clinical presentations and molecular basis of complement C1r deficiency in a male African-American patient with systemic lupus erythematosus[J]. Lupus, 2011, 20:1126-1134. doi:  10.1177/0961203311404914
    [17] Crow YJ, Chase DS, Schmidt JL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1[J].Am J Med Genet A, 2015, 167A:296-312. https://www.escholar.manchester.ac.uk/uk-ac-man-scw:263148
    [18] Butbul AY, Mandel H, Hersh EA, et al. Prolidase deficiency associated with systemic lupus erythematosus (SLE):single site experience and literature review[J].Pediatr Rheumatol Online J, 2012,10:18. doi:  10.1186/1546-0096-10-18
    [19] Ellyard JI, Jerjen R, Martin JL, et al. Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing[J]. Arthritis Rheumatol, 2014, 66:3382-3386. doi:  10.1002/art.38824
    [20] Hedrich CM, Smith EMD, Beresford MW. Juvenile-onset systemic lupus erythematosus (jSLE)-pathophysiological concepts and treatment options[J].Best Pract Res Clin Rheumatol, 2017, 31:488-504. doi:  10.1016/j.berh.2018.02.001
    [21] Hakkim A, Fürnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis[J]. Proc Natl Acad Sci U S A,2010,107:9813-9818. doi:  10.1073/pnas.0909927107
    [22] Wilkinson MGL, Rosser EC. B cells as a therapeutic target in paediatric rheumatic disease[J]. Front Immunol, 2019,10:214. doi:  10.3389/fimmu.2019.00214
    [23] Edelbauer M, Kshirsagar S, Riedl M, et al. Activity of childhood lupus nephritis is linked to altered T cell and cytokine homeostasis[J].J Clin Immunol, 2012, 32:477-487. doi:  10.1007/s10875-011-9637-0
    [24] Crispin JC, Hedrich CM, Suárez-Fueyo A, et al. SLE-associated defects promote altered T cell function[J]. Crit Rev Immunol, 2017, 37:39-58. doi:  10.1615/CritRevImmunol.2018025213
    [25] Menon M, Blair PA, Isenberg DA, et al. A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus[J].Immunity, 2016, 44:683-697. doi:  10.1016/j.immuni.2016.02.012
    [26] Knight JS,Kaplan MJ. Lupus neutrophils:'NET' gain in understanding lupus pathogenesis[J]. Curr Opin Rheumatol,2012,24:441-450. doi:  10.1097/BOR.0b013e3283546703
    [27] Kaul A, Gordon C, Crow MK,et al. Systemic lupus erythematosus[J]. Nat Rev,2016,2:1-21. https://www.cdc.gov/lupus/facts/detailed.html
    [28] Samanta M, Nandi M, Mondal R, et al. Childhood lupus nephritis:12 years of experience from a developing country's perspective[J]. Eur J Rheumatol, 2017, 4:178-183. doi:  10.5152/eurjrheum.2017.16117
    [29] Al-Mayouf SM, AlAmeer A, Alfattani A, et al. Outcome of childhood lupus nephritis in Saudi children[J].Saudi J Kidney Dis Transpl, 2017,28:1015-1020. doi:  10.4103/1319-2442.215142
    [30] Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis:the SHARE initiative[J]. Ann Rheum Dis,2017,76:1965-1973. doi:  10.1136/annrheumdis-2017-211898
    [31] Ambrose N, Morgan TA, Galloway J, et al. Differences in disease phenotype and severity in SLE across age groups[J].Lupus, 2016, 25:1542-1550. doi:  10.1177/0961203316644333
    [32] Groot N, de Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of childhoodonset systemic lupus erythematosus:the SHARE initiative[J].Ann Rheum Dis, 2017,76:1788-1796. doi:  10.1136/annrheumdis-2016-210960
    [33] Vega-Fernandez P, Vanderburgh White S, Zelko F, et al. Cognitive Performance scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood Onset systemic lupus erythematosus[J]. Arthritis Care Res, 2015,67:1119-1127. doi:  10.1002/acr.22571
    [34] Abdwani R, Abdalla E, Al-Zakwani I.Unique characteris-tics of prepubertal onset systemic lupus erythematosus[J]. Int J Pediatr, 2019, 9537065. http://downloads.hindawi.com/journals/ijpedi/2019/9537065.pdf
    [35] Gomes RC, Silva MF, Kozu K, et al.Features of 847 childhood-onset systemic lupus erythematosus patients in three age groups at diagnosis:a Brazilian Multicenter Study[J]. Arthritis Care Res (Hoboken),2016, 68:1736-1741. doi:  10.1002/acr.22881
    [36] Groot N, Graeff N, Avcin T, et al. European evidence-based recommendations for diagnosis and treatment of pediatric antiphospholipid syndrome:the SHARE initiative[J]. Ann Rheum Dis,2017,76:1637-1641. doi:  10.1136/annrheumdis-2016-211001
    [37] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythe-matosus[J]. Arthritis Rheum, 2019,71:1400-1412. doi:  10.1002/art.40930
    [38] Groot N, Shaikhani D, Teng YKO, et al. Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus[J]. Arthritis Rheum, 2019, 71:290-301. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=192e6d7bbf75f7f0220c1d25afa028c0
    [39] Smith EMD, Lythgoe H, Midgley A, et al. Juvenile-onset systemic lupus erythematosus:Update on clinical presentation, pathophysiology and treatment options[J]. Clin Immun, 2019, 209:1-12. https://www.ncbi.nlm.nih.gov/pubmed/31678365
    [40] Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78:736-745. doi:  10.1136/annrheumdis-2019-215089
    [41] Morgan TA, Watson L, McCann LJ,et al. Children and adolescents with SLE:not just little adults[J]. Lupus, 2013, 22:1309-1319. doi:  10.1177/0961203313502863
    [42] Mina R, von Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus[J]. Arthritis Care Res,2012,64:375-383. doi:  10.1002/acr.21558
    [43] Deng J, Chalhoub NE, Sherwin CM, et al. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus[J]. Semin Arthritis Rheum, 2019, 49:251-259. doi:  10.1016/j.semarthrit.2019.03.010
    [44] Michaud M, Catros F, Ancellin S, et al. Treatment of systemic lupus erythematosus:don't forget hydroxychloroquine[J]. Ann Rheum Dis, 2019.doi:10.1136/annrheumdis-2019-215799.[Epub ahead of print].
    [45] Marmmor MF, Kellner U, Lai TY, et al. Recommendations on screening for Chloroquine and hydroxychloroquine retinopathy (2016 Revision)[J]. Ophthalmology,2016,123:1386-1394. doi:  10.1016/j.ophtha.2016.01.058
    [46] Tian SY, Silverman ED, Pullenayegum E, et al. Com-parative effectiveness of mycophenolate mofetil for the treatment of juvenile-onset proliferative lupus nephritis[J].Arthritis Care Res (Hoboken),2017, 69:1887-1894. doi:  10.1002/acr.23215
    [47] Chan VS, Tsang HH, Tam RC, et al. B-cell-targeted therapies in systemic lupus erythematosus[J]. Cell Mol Immunol, 2013,10:133-142. doi:  10.1038/cmi.2012.64
    [48] Peterknecht E, Keasey MP, Beresford MW. The effective-ness and safety of biological therapeutics in juvenile-onset systemic lupus erythematosus (JSLE):a systematic review[J]. Lupus, 2018,27:2135-2145. doi:  10.1177/0961203318804879
    [49] 贺成美,张奉春.贝利木单克隆抗体:治疗系统性红斑狼疮的新型靶向药物[J].协和医学杂志,2020,11:130-134. http://oldmed.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_xhyx202002003
    [50] Brunner HI, Martini A, Lovell DJ, et al. Clinical trials in children and adolescents with systemic lupus erythematosus:methodological aspects, regulatory landscape and future opportunities[J].2019,78:162-170.
    [51] Ruperto N, Abud-Medonza C, Viola DO, et al. The PLUTO study:Intravenous Belimumab in Children with Systemic Lupus Erythematosus[C]. 2019 EULAR Annual European Congress of Rheumatology, 2019.
    [52] Rodriguez-Smith J,Brunner HI. Update on the treatment and outcome of systemic lupus erythematous in children[J]. Curr Opin Rheumatol,2019, 31:464-470. doi:  10.1097/BOR.0000000000000621
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  310
  • HTML全文浏览量:  181
  • PDF下载量:  132
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-03-10
  • 刊出日期:  2020-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！